Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure);Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences);and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8607691
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2018-12-31
Budget Start
2014-03-13
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$5,199,621
Indirect Cost
$2,273,554
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Wen, Hannah Y; Brogi, Edi (2018) Lobular Carcinoma In Situ. Surg Pathol Clin 11:123-145
Aghajanian, Carol; Bell-McGuinn, Katherine M; Burris 3rd, Howard A et al. (2018) A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs 36:1016-1025
Pun, Shawn C; Landau, Heather J; Riedel, Elyn R et al. (2018) Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. J Am Soc Echocardiogr 31:64-70
Ring, Brian Z; Murali, Rajmohan; Soslow, Robert A et al. (2018) Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiol Biomarkers Prev 27:680-688
Shukla, Sachet A; Bachireddy, Pavan; Schilling, Bastian et al. (2018) Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell 173:624-633.e8
Chaft, Jamie E; Dagogo-Jack, Ibiayi; Santini, Fernando C et al. (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67-71
Petrovic, Ivana D; Migliacci, Jocelyn; Ganly, Ian et al. (2018) Ameloblastomas of the mandible and maxilla. Ear Nose Throat J 97:E26-E32
Nashat, Melissa A; Ricart Arbona, Rodolfo J; Lepherd, Michelle L et al. (2018) Ivermectin-compounded Feed Compared with Topical Moxidectin-Imidacloprid for Eradication of Demodex musculi in Laboratory Mice. J Am Assoc Lab Anim Sci 57:483-497
Roxburgh, Campbell S; Fenig, Yaniv M; Cercek, Andrea et al. (2018) Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Ann Surg Oncol :

Showing the most recent 10 out of 8799 publications